Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SLN

HOLD

Silence Therapeutics plc · Healthcare · United Kingdom · $521M · Avg Vol: $7M/d

36
StockRank
Get insider-trade alerts
Q
26
V
21
M
81
P/E (TTM)
ROE
-92.6%
D/E
0.0x
Dividend %
Loading 1Y...
PRICE (1Y)+80.4%
6.698.039.3810.7212.07Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$12.07
RSI (14)
64.7
52W High
$12.19
From 52W High
1.0%

SCORE BREAKDOWN

Quality
26
ROIC
-65.4%11.0
ROE
-92.6%9.8
GP/Assets
0.5%12.3
Op. Margin
-3565.4%4.4
FCF/Assets
-47.4%5.9
Piotroski
239.0
Int. Cover
N/A
D/E Ratio
0.00x90.9
Current Ratio
9.83x86.2
Value
21
P/E (TTM)
N/A
EV/EBITDA
-6.3x25.0
P/FCF
N/A
P/B
10.5x10.6
P/S
620.4x3.4
Div Yield
N/A
Momentum
81
52W High %
99%98.6
RS 6M
105%98.0
SMA 50/200
1.24x91.8
EPS Rev 4W
N/A
EPS Rev 12W
N/A
EPS Improve
+76%66.3
Q Growth
N/A

FUNDAMENTALS

Market Cap
$521M
P/E (Forward)
-28.3x
Gross Margin
79.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SLN are excluded.

TickerCompanyMkt CapStockRankSignal
SLNSilence Therapeutics plc(you)$521M36HOLD
AUTLAutolus Therapeutics plc$386M32SELL
AVCT.LAvacta Group Plc$489M12STRONG SELL
OXB.LOxford Biomedica plc$1.0B14STRONG SELL
IMCRImmunocore Holdings plc$1.8B48HOLD
SCLP.LScancell Holdings plc$252M10STRONG SELL
BCYCBicycle Therapeutics plc$270M8STRONG SELL
ONT.LOxford Nanopore Technologies plc$1.6B16STRONG SELL
GNS.LGenus plc$1.9B54HOLD
POLB.LPoolbeg Pharma PLC$63M24SELL

Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 55.5%

Silence Therapeutics plc (SLN) — Stock Score Summary

Silence Therapeutics plc (SLN) has a MoatMap StockRank of 36/100 based on Quality (26/100), Value (21/100), and Momentum (81/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price$12.07
Market Cap$521M
P/E (Forward)-28.26
Price/Book10.54
Return on Equity-92.6%
Return on Invested Capital-65.4%
Debt/Equity0.00x
Gross Margin79.5%
Operating Margin-3565.4%
Revenue Growth197.2%
Free Cash Flow$-62M

Silence Therapeutics plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Silence Therapeutics plc’s (SLN) StockRank?
MoatMap’s StockRank for Silence Therapeutics plc (SLN) is 36/100, with a Hold signal. It is a composite of Quality (26), Value (21), and Momentum (81) factor ranks across MoatMap’s 20,000+ stock universe.
Does Silence Therapeutics plc have an economic moat?
Silence Therapeutics plc (SLN) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Silence Therapeutics plc a buy, hold, or sell?
MoatMap’s current signal for Silence Therapeutics plc (SLN) is Hold, based on a StockRank of 36/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Silence Therapeutics plc in?
Silence Therapeutics plc (SLN) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).